Aminophylline reduces the risk of death in people with septic shock.

Published Date: 10 Mar 2023

A recent study by Ruifang Zhang and colleagues showed that aminophylline reduced the risk of death and prolonged survival in patients with sepsis. more...

Read Full News

Todays Updates


This Week on NeurologyLive® — September 28, 2026 Isabella Ciccone, MPH


Here's some of what is coming soon to NeurologyLive® this week.

Somnolence Risk, Short-Term Efficacy Drive VMAT2 Inhibitor Choice in Older Adults With Tardive Dyskinesia Isabella Ciccone, MPH


In a discrete choice experiment, somnolence risk and short-term efficacy were the top factors driving vesicular monoamine transporter 2 inhibitor selection for tardive dyskinesia in patients aged 55 years and older.

FDA Approves Tavapadon for the Treatment of Parkinson Disease Isabella Ciccone, MPH


FDA approves once-daily oral tavapadon for Parkinson disease, a first-in-class D1/D5 partial agonist that improves motor function and ON time, with key safety warnings.

Gefurulimab Cuts Hospitalizations, Sustains Response in Phase 3 PREVAIL Trial of Myasthenia Gravis Marco Meglio


New PREVAIL trial analyses presented at the 2026 AANEM Annual Meeting showed gefurulimab reduced gMG-related hospitalizations and produced durable symptom and quality-of-life gains through one year.

SHIELD Trial Advances Combination Antiviral for Long COVID Marco Meglio


PridCor Therapeutics is moving its phase 2 SHIELD trial of a combination antiviral regimen toward enrollment, building on case series data showing durable symptom improvement in long COVID.

Inebilizumab Shows Durable Benefit in MuSK+ Generalized Myasthenia Gravis at AANEM 2026 Marco Meglio


New phase 3 MINT trial analyses presented at the 2026 AANEM Annual Meeting showed inebilizumab produced sustained improvement in MuSK-positive gMG regardless of time since diagnosis.

5 Nephrology Headlines You Missed in August 2026 Alex Hillenbrand


A joint ESC/ERA guideline on universal CKD screening headlines August 2026's nephrology news, alongside new finerenone and sibeprenlimab trial data.

Todays Updates


This Week on NeurologyLive® — September 28, 2026 Isabella Ciccone, MPH


Here's some of what is coming soon to NeurologyLive® this week.

Somnolence Risk, Short-Term Efficacy Drive VMAT2 Inhibitor Choice in Older Adults With Tardive Dyskinesia Isabella Ciccone, MPH


In a discrete choice experiment, somnolence risk and short-term efficacy were the top factors driving vesicular monoamine transporter 2 inhibitor selection for tardive dyskinesia in patients aged 55 years and older.

FDA Approves Tavapadon for the Treatment of Parkinson Disease Isabella Ciccone, MPH


FDA approves once-daily oral tavapadon for Parkinson disease, a first-in-class D1/D5 partial agonist that improves motor function and ON time, with key safety warnings.

Gefurulimab Cuts Hospitalizations, Sustains Response in Phase 3 PREVAIL Trial of Myasthenia Gravis Marco Meglio


New PREVAIL trial analyses presented at the 2026 AANEM Annual Meeting showed gefurulimab reduced gMG-related hospitalizations and produced durable symptom and quality-of-life gains through one year.

SHIELD Trial Advances Combination Antiviral for Long COVID Marco Meglio


PridCor Therapeutics is moving its phase 2 SHIELD trial of a combination antiviral regimen toward enrollment, building on case series data showing durable symptom improvement in long COVID.

Inebilizumab Shows Durable Benefit in MuSK+ Generalized Myasthenia Gravis at AANEM 2026 Marco Meglio


New phase 3 MINT trial analyses presented at the 2026 AANEM Annual Meeting showed inebilizumab produced sustained improvement in MuSK-positive gMG regardless of time since diagnosis.

5 Nephrology Headlines You Missed in August 2026 Alex Hillenbrand


A joint ESC/ERA guideline on universal CKD screening headlines August 2026's nephrology news, alongside new finerenone and sibeprenlimab trial data.

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Pediatric high-grade gliomas: Research reveals effective targeting with avapritinib

2.

Risk of a second cancer after early breast cancer is low, say new findings

3.

Non-Hodgkin lymphomas that are indolent have been linked to psychological distress.

4.

According to a study, male testicular cancer risk is linked to neurodevelopmental disorders.

5.

Colon cancer and exercise: Can physical activity reprogram genes?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot